Table 1.

Pattern of immune checkpoint inhibitor-induced pulmonary adverse events

Nivolumab	Interstitial lung disease, pneumonitis, OP, AFOP, sarcoidosis/sarcoid-like reaction, pleural effusion, reactivation of pulmonary infection (tuberculosis, aspergillosis), lung cavitation, asthma.
Pembrolizumab	Pneumonitis (increased risk of high-grade pneumonitis compared with nivolumab), pleural effusion, sarcoidosis/sarcoid-like reactions, reactivation of tuberculosis, AFOP, OP, eosinophilic pneumonia, ARDS, lung cavitation, asthma exacerbation, alveolar hemorrhage.
Nivolumab/ipilimumab	Pneumonitis (increased risk of all-grade pneumonitis compared with PD-1 inhibitor monotherapy), sarcoidosis.
Atezolimumab	Pneumonitis (overall, PD-L1 inhibitors have a lower incidence of all-grade pneumonitis compared with PD-1 inhibitors).
Durvalumab	Pneumonitis
Avelumb	Pneumonitis, sarcoid-like reaction

AFOP, Acute Fibrinous Organizing Pneumonia; ARDS, Acute Respiratory Distress Syndrome; OP, organizing pneumonia; PD-1, Programmed Death-1; PD-L1, Programmed Death-Ligand 1.